[New adrenergic blocking agent Visken (LB-46) in the treatment of chronic coronary disease].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013565:Sympatholytics / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D007211:Indoles; D013565:Sympatholytics
Nowy lek blokujacy receptory beta adrenergiczne Visken (LB-46) w leczeniu niewydolności wieńcowej.